Lexicon Pharmaceuticals, Inc. entered into a Preferred Stock Purchase Agreement with certain accredited investors to sell 2,304,147 shares of Series A Convertible Preferred Stock at a price of $108.50 per share in a private placement, resulting in gross proceeds of approximately $250 million.